The collaboration will leverage the distinct strengths of each organisation with a focus on developing novel therapeutics for patients across multiple disease areas. King’s has one of the leading scientific discovery portfolios worldwide and will contribute biological research breakthroughs with the potential to create high-impact medicines. In addition, the university’s associated hospitals and clinician scientists are ideally positioned to provide support to programs during clinical development. Apollo’s translational scientists and drug development architects will progress these research programs under Apollo’s asset-centric portfolio model to rapidly and efficiently bring those with the greatest promise through clinical investigation and ultimately to patients.

“When looking at research output, King’s College London is one of the largest and most successful centers for biomedical research and education in the UK and indeed globally. With its broad clinical presence, we have also found King’s has exceptional insight in selecting and advancing research that can translate effectively into therapeutic programs,” said Dr Richard Mason, chief executive officer of Apollo. "We are proud to initiate this partnership with our newest collaborator as we look to grow both our portfolio of programs and our relationships with the world’s leading scientists and biomedical institutions. This collaboration continues to build on recent the progress we have made in advancing our internal pipeline, building our team and establishing our US operations in Cambridge, Mass.”

King’s College London joins Apollo alongside Imperial College London, University College London, and the University of Cambridge.